Affimed shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 study in non-small cell lung cancer (NSCLC).
TDS announced definitive deal to sell OneNeck IT Solutions and Data Center Holdings to US Signal. Expected to close in Q3 2024, provides additional capital for TDS Telecom's fiber program.
Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates.